No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
Aptose Biosciences Faces Nasdaq Delisting Challenge
Aptose Announces Receipt of Deficiency Notice From Nasdaq
Aptose Announces Results From Annual and Special Meeting of Shareholders
Press Release: Aptose Announces Results From Annual and Special Meeting of Shareholders
H.C. Wainwright Maintains Aptose Biosciences(APTO.US) With Buy Rating, Maintains Target Price $7
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress